Fluidigm Introduces Three Imaging Mass Cytometry Panel Kits and Advanced CyTOF Software to Accelerate Immuno-Oncology Research
Imaging Mass Cytometry is rapidly advancing our understanding of health and disease by empowering researchers around the globe to deeply profile cellular phenotypes in tumors and tissues. The new ready-to-go Maxpar panel kits for immuno-oncology studies can enable researchers to rapidly profile immune infiltrates across a range of human cancer types and treatment modalities with Imaging Mass Cytometry.
Developed using pathologist-verified antibodies, the panels can be mixed and matched to profile tumor-infiltrating lymphocytes, immune cell activation states and tissue architecture. By combining them as a single 18-marker panel, researchers can broadly profile activated tumor-infiltrating lymphocytes for single-cell analysis of the tumor architecture, all from a single tissue scan. Customization is also simplified using CyTOF technology, enabling researchers to easily add more than 10 markers to support specific translational and clinical research studies.
Cellular biomarker identification from multiple user-defined locations in the tumor microenvironment is also simplified using the Hyperion™ Imaging System. The advanced CyTOF Software streamlines the selection and acquisition of multiple regions of interest (ROIs) from each slide with an enhanced user experience. Researchers can remotely annotate each ROI using bright field reference images to guide automated batch acquisition of highly multiplexed images on the system at 1-micron resolution. During image acquisition, researchers can visualize multiplexed images in real time across all detection channels to ensure data quality.
“Immunotherapy is revolutionizing cancer treatment,” said Chris Linthwaite, President and CEO of Fluidigm. “By delivering pre-designed Imaging Mass Cytometry panels and enhanced software, we will accelerate the development of better biomarkers and more effective immunotherapies.”
Forward-Looking Statement for
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the anticipated benefits of newly introduced products and the growth and potential of immune profiling and
Senior Director, Marketing
650 737 4190
Vice President, Investor Relations
650 416 7423
Source: Fluidigm Corporation